Navigation Links
SanBio Receives FDA Clearance to Initiate Cell Therapy Clinical Studies for Stroke Recovery
Date:6/16/2010

MOUNTAIN VIEW, Calif., June 16 /PRNewswire/ -- SanBio Inc. (www.san-bio.com) announced today that the United States Food and Drug Administration (FDA) has approved the clinical testing of their SB623 regenerative medicine product in patients suffering from disability caused by cerebral stroke. SB623 is derived from bone marrow stromal cells (MSCs) isolated from healthy adult donors.

This Phase 1/2a clinical trial will test the safety of SB623 when implanted in the damaged regions of the brains of stable stroke patients. "We are pleased and proud to be given the opportunity to move this therapeutic approach forward. This is the only clinical trial currently open in the United States testing the regenerative potential of cell therapy in the brain," said Kieta Mori, co-CEO of SanBio. "This cell product has the potential to change the lives of patients afflicted by stroke injury," said Dr. Douglas Kondziolka, the Peter J. Jannetta Professor of Neurological Surgery in the Department of Neurological Surgery, Director, Center for Brain Function and Behavior at the University of Pittsburgh School of Medicine and a Principal Investigator in the SB623 clinical trial. According to the American Heart Association, stroke is the third leading cause of death in the United States and the leading cause of serious long-term disability. "Cell therapy has great potential in many degenerative diseases of the central nervous system. SB623's entry into human clinical testing marks an important step forward for the field," said Dr. Gary Steinberg, the Lacroute-Hearst Professor, Chairman of the Department of Neurosurgery, and Director of the Stanford Institute for Neuro-Innnovation and Translational Neurosciences at the Stanford University School of Medicine. Dr. Steinberg is also a Principal Investigator in the SB623 clinical trial.

About SB623: SB623 is a proprietary population of regenerative cells derived from genetically engineered bone marrow stromal cells (MSCs) obtained from healthy adult donors. SB623 is implanted directly adjacent to the area damaged by stroke and functions by producing proteins that aid the healing process. The development of SB623 is based on earlier research by Professor Mari Dezawa of Tohoku University.

About SanBio: SanBio is a privately held San Francisco Bay Area biotechnology company focused on the discovery and development of regenerative cell therapy products.


'/>"/>
SOURCE SanBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... TapImmune, Inc. (NASDAQ: TPIV), ... of innovative peptide and gene-based immunotherapeutics for the ... that it will participate in two upcoming Investor ... Wilson , Chairman and CEO of TapImmune, will ... pipeline and partnering opportunities for its proprietary PolyStart ...
(Date:3/22/2017)... , March 22, 2017 Hologic, Inc. ... has completed the acquisition of Cynosure, Inc., a leader ... share in cash. "We are pleased to ... working with Michael Davin and the entire ... large, rapidly growing medical aesthetics market," said Steve ...
(Date:3/22/2017)... 2017 TFS is pleased to announce the ... Tumaian , two global executive positions in Medical Affairs and Clinical ... Leadership Team and will report to Dr. Montse Barceló , ... ... 10 years of medical and scientific expertise gained across leading biopharmaceutical ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... Drs. Jennifer Houck, Lauren Smith, ... to accept new patients in need of skilled pediatric dentistry in Rock ... Care offers pediatric patients routine treatments, including cavities, sealants and fluoride applications, in a ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... core lab with extensive therapeutic experience and operational excellence in oncology clinical trials, ... clinical trial for the treatment of non-small cell lung cancer and small cell ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... planning, and related services to communities across eastern Texas, is announcing a charity ... providing meals to hungry children and adults. , Consistently a top-rated nonprofit ...
(Date:3/22/2017)... ... ... Chris Humphrey Insurance Agency, a North Carolina firm offering asset protection services and ... initiating a charity event to raise support for five year old Dillyn, a young ... Friday evening in September 2014. At the time, Dillyn was only four years old, ...
(Date:3/22/2017)... ... March 22, 2017 , ... HumanHaus is proud to announce the launch ... broom was great when it was invented, but our customers today are busy, energetic, ... social young couple, the empty nesters and retired that want to travel. ...
Breaking Medicine News(10 mins):